METYROSINE

Post-LOE

metyrosine

Leadingtac Pharmaceutical
ANDAORALCAPSULE
Approved
Sep 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT01127503Phase 2Terminated

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

Started Jun 2010
Company
Leadingtac Pharmaceutical
Leadingtac Pharmaceutical
China - Shanghai
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers